Loading clinical trials...
Loading clinical trials...
Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Boehringer Ingelheim
NCT06855771 · Carcinoma, Non-Small-Cell Lung
NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, and more
NCT06120140 · Carcinoma, Non-Small-Cell Lung
NCT04165798 · Carcinoma, Non-Small-Cell Lung
NCT06667908 · Carcinoma, Non-Small-Cell Lung
HOP d'Angers
Angers
HOP Jean Minjoz
Besançon
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
Großhansdorf
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions